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Eukaryotic genomes encode a zinc finger protein (ZPR1) with
tandem ZPR1 domains. In response to growth stimuli, ZPR1 assem-
bles into complexes with eukaryotic translation elongation factor
1A (eEF1A) and the survival motor neurons protein. To gain insight
into the structural mechanisms underlying the essential function of
ZPR1 in diverse organisms, we determined the crystal structure of
a ZPR1 domain tandem and characterized the interaction with
eEF1A. The ZPR1 domain consists of an elongation initiation factor
2-like zinc finger and a double-stranded  helix with a helical
hairpin insertion. ZPR1 binds preferentially to GDP-bound eEF1A
but does not directly influence the kinetics of nucleotide exchange
or GTP hydrolysis. However, ZPR1 efficiently displaces the ex-
change factor eEF1B from preformed nucleotide-free complexes,
suggesting that it may function as a negative regulator of eEF1A
activation. Structure-based mutational and complementation anal-
yses reveal a conserved binding epitope for eEF1A that is required
for normal cell growth, proliferation, and cell cycle progression.
Structural differences between the ZPR1 domains contribute to the
observed functional divergence and provide evidence for distinct
modalities of interaction with eEF1A and survival motor neuron
complexes.
growth factor receptor  structure  neurodegeneration 
spinal muscular atrophy  cell cycle
ZPR1 was identified as a zinc finger (ZnF) protein that bindsto the inactive form of the EGF receptor in quiescent cells
and is released after activation (1). In proliferating cells treated
with mitogens or other growth stimuli, ZPR1 binds directly to
eukaryotic translation elongation factor 1A (eEF1A) (2), as-
sembles into multiprotein complexes with the survival motor
neurons (SMN) protein (3), and accumulates in subnuclear
structures (gems and Cajal bodies) (1, 3, 4). Targeted disruption
of the ZPR1 gene in yeast (2) and mice (5) indicates that ZPR1
is essential for viability in diverse eukaryotic organisms. Reduc-
tion of ZPR1 expression in mammalian cells by antisense or
siRNA knockdown causes defects in transcription, prevents
DNA synthesis, and results in an accumulation of cells in the G1
and G2 phases of the cell cycle (6).
The interaction of ZPR1 with SMN complexes is disrupted in
cells derived from patients with spinal muscular atrophy (SMA)
(3), an autosomal recessive disease linked to mutations in the
telomeric copy of the SMN1 gene and characterized by progres-
sive loss of spinal cord motor neurons during early childhood (7,
8). Interestingly, ZPR1 is expressed at low levels in patients with
severe forms of SMA and at significantly higher levels in
unaffected siblings with an identical SMN1 mutation (9). Con-
sistent with this observation, Zpr1/mice exhibit axonal defects
and degeneration of spinal cord motor neurons (10). Recent
studies suggest that the neurodegenerative phenotype ofZpr1/
mice, and potentially the severity of SMA also may be related to
the interaction with eEF1A. Mammalian genomes contain two
eEF1A genes, eEF1A1 and eEF1A2, which encode proteins that
are 92% identical (11). Expression of eEF1A2 is restricted to
terminally differentiated cells of skeletal muscle, heart, and
brain and dominates in the postnatal period (12). Loss of
eEF1A2 expression because of mutation of the eEF1A2 gene in
wasted (wst) mice results in progressive motor neuron degener-
ation, muscle atrophy, paralysis, and death within 30 days after
birth (12–14). The neurodegenerative phenotype of wst mice is
similar to that of Zpr1/mice (10) as well as mice with reduced
expression of SMN (15, 16).
ZPR1 has a broadly conserved tandem architecture [Fig. 1A and
supporting information (SI) Fig. 6] consisting of a duplicated
module designated the ‘‘ZPR1 domain’’ in the SMART database
(17). The ZPR1 domain is in fact a composite of two apparently
modular domains: a C4-type Zn2 finger and an 130-residue
domain of unknown tertiary structure.Hereafter, we refer to theN-
and C-terminal ZPR1 domains as the ZnF1-A domain and ZnF2-B
domain modules, respectively. A homologous protein containing a
single ZPR1 domain is present in Archae bacteria, suggesting that
the tandem architecture arose early in the evolution of eukaryotic
organisms through successive gene duplication and fusion events.
Complementation analyses in yeast demonstrate that the ZnF2-B
domain module is required for viability, whereas the ZnF1-A
domainmodule is required for normal cell growth and proliferation
(2). The interaction with the inactive EGF receptor is mediated by
the ZnFs, whereas the binding sites for eEF1A and the SMN
complex are located within the ZnF1-A domain and ZnF2-B
domain modules, respectively (1–3).
Despite the essential role of ZPR1 in diverse cellular pro-
cesses, including growth, proliferation, and neurodegeneration,
little is known about the structural bases for interaction with
receptors, eEF1A, and SMN complexes. Furthermore, it is
unclear how ZPR1 binding depends on and/or regulates the
GTPase cycle of eEF1A or whether the interaction with eEF1A
is required for any of the cellular functions previously associated
with the ZnF1-A domain region of ZPR1. To address these
questions and gain insight into the underlying structural bases,
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we determined the crystal structure of a nearly full-length
construct of ZPR1; identified conserved surfaces that likely
mediate interactions with receptors and SMN complexes; char-
acterized the nucleotide dependence of ZPR1 binding to eEF1A
as well as the effect on the GTPase cycle; mapped the eEF1A
binding epitope by mutational analysis; and assessed the effect
of disrupting the interaction with eEF1A on cell growth, pro-
liferation, and cell cycle progression.
Results
Tertiary Structure of a ZPR1 Domain Tandem. Crystals of a ZPR1
domain tandem were obtained for a construct corresponding
to residues 46–440 of mouse ZPR1. The structure of the
selenomethionine-substituted form was determined by single-
wavelength anomalous diffraction (SAD) at the f maximum of
the selenium edge and refined to 2.0 Å (SI Table 1 and SI Fig.
7). Continuous density was observed throughout the ZnF1-A
domain and ZnF2-B domain modules; however, residues 235–
244 in the variable linker region between the A domain and
ZnF2 were disordered. One possibility depicted in Fig. 1B is
that the disordered residues connect nearest neighbors, which
are separated by distance of 13 Å. In this case, the relative
orientations of ZnF1, the A domain, and the ZnF2-B domain
module would be constrained by intermolecular contacts
within a crystallographic dimer (SI Fig. 7B Left) as well as
lattice contacts between crystallographic dimers. The only
other possibility would require that the disordered linker
region adopt a largely extended configuration to span the
longer distance of 29 Å between next nearest neighbors (SI Fig.
7B Right). In this case, the relative orientation of the various
domains would be constrained as described above, with the
exception that the contact between the A domain and ZnF2
would be intramolecular, giving rise to a more organized
arrangement of the A domain with respect to the ZnF2-B
domain tandem. Given that full-length ZPR1 as well as the
construct used for crystallization run as monomers on gel
filtration even at concentrations approaching 1 mM (data not
shown), the physiological significance of the crystallographic
dimer, if any, is unclear. Likewise, we find no evidence to
support an interaction between the A domain and the ZnF2-B
domain module in solution by either coprecipitation or iso-
thermal titration calorimetry (data not shown). On the other
hand, as discussed below, residues in the A domain that contact
ZnF2 in the crystallographic dimer are important for binding
to eEF1A.
The ZnFs consist of a four-stranded antiparallel -sheet
stabilized by a zinc-binding site located at one end (Fig. 1B). A
search for structural homologues by tertiary structural compar-
ison using secondary structure matching (18) revealed a high
degree of structural similarity with the three-stranded antipar-
allel ZnF of elongation initiation factor 2 (eIF2; rmsd, 1.5 Å)
(Fig. 1C). The A and B domains share a common composite fold
consisting of a helical hairpin inserted within a double-stranded,
antiparallel -helix (Fig. 1B). Apart from the hairpin insertion
and differences in loops, the -helix in the ZPR1 A and B
domains is most similar to that in the Trp RNA-binding atten-
uation protein (rmsd, 3.2 Å) (Fig. 1D). In contrast to the Trp
RNA-binding attenuation protein, for which the -helix facili-
tates formation of a stable elevenfold symmetric ring, ZPR1 runs
as a monomer on gel filtration (data not shown).
Although ZnF1 and ZnF2 have similar tertiary structures
(rmsd, 1.6 Å; SI Fig. 8A), variations occur in the NH2-terminal
strand, which is longer in ZnF2, and in the Zn2 binding site,
which is well ordered in ZnF1 but exhibits relatively high
B-factors in ZnF2 (SI Fig. 7C). The largest differences in the A
and B domains occur in the helical hairpins and at the C
terminus, which adopts a helical conformation in the A domain
compared with an extended conformation in the B domain (SI
Fig. 8A). The differences in the helical hairpins reflect dissimilar
amino acid sequences encoding the 1 helices (SI Fig. 8B) and
contribute to the functional divergence of the A and B domains.
Potential Conserved Binding Surfaces for Receptors and SMN Com-
plexes. Biochemical studies have shown that: (i) both Zn2 finger
domains can bind independently to inactive tyrosine kinase
receptors, including the EGF and PDGF receptors (1); (ii) the
ZnF1-A domain module is sufficient for eEF1A binding (2); and
(iii) the B domain is required for binding to the SMN complex
(3). Although ZPR1 binds directly to receptors and eEF1A, the
particular components of the SMN complex that mediate the
interaction with ZPR1 have not yet been identified. Likewise, it
is not yet known whether the A and B domains are sufficient for
Fig. 1. Domain organization and tertiary structure of ZPR1. (A) Schematic illustration of the modular architecture of ZPR1, which consists of two homologous
Zn2 finger-A/B domain modules. (B) Ribbon representation of the tertiary structure of ZPR1. (C) Structural alignment of the first ZnF in ZPR1 with the ZnF in
eEIF2. (D) Structural alignment of the -helix in the ZPR1 A domain with the -helix in the Trp RNA-binding protein TRAP.








the interactions with eEF1A and the SMN complex or whether
these interactions also require ZnF1 and ZnF2, respectively. In
ZnF1 and ZnF2, the exposed residues that are conserved
between the two ZnFs cluster in two patches (Fig. 2A and SI Fig.
9), one or both of which could contribute to the interaction with
receptors. In the ZnF2-B domain module, the majority of
exposed residues that are conserved among ZPR1 homologues
cluster in two distinct patches located at the interface between
ZnF2 and the B domain (Fig. 2B and SI Fig. 10). The conserved
surface residues in both patches are distributed roughly evenly
between the two domains, which adopt a specific organized
tertiary structure with a substantial buried surface area of 1,000
Å2. The majority of residues that are buried at the interface
between ZnF2 and the B domain are highly conserved (Fig. 2C).
ZPR1 Binds Preferentially to GDP-Bound eEF1A. Although eEF1A
binds directly to the ZnF1-A domain region of ZPR1 (2), the
nucleotide dependence of the interaction and effect on the
GTPase cycle of eEF1A have not been investigated. To further
characterize the interaction of ZPR1 with eEF1A, we developed
a quantitative binding assay that takes advantage of the envi-
ronmentally sensitive emission of a methylanthraniloyl [2-(3)-
bis-O-(N-methylanthraniloyl (mant)] f luorophore attached to
the 2/3 hydroxyl groups of GDP or the nonhydrolyzeable GTP
analogue guanyl-5yl-imidodiphosphate. As shown in Fig. 3A,
the emission intensity of mant–GDP-loaded eEF1A increases
after titration with full-length ZPR1. The increase in emission
intensity as a function of ZPR1 concentration has a hyperbolic
shape characteristic of a binding isotherm and saturates in the
high nanomolar range at a maximum increase of 10%. Titra-
tion with a truncated ZnF1-A domain construct (ZPR11–240)
yields equivalent results, whereas a control titration with the
corresponding ZnF2-B domain construct (ZPR1246–459), which
does not coprecipitate eEF1A (2), has no significant effect on
the emission intensity even at much higher concentrations. The
data are well described by a simple 1:1 binding model, yielding
indistinguishable dissociation constants (Kd) of 170 and 160 nM
for full-length ZPR1 and ZPR11–240, respectively. The affinity of
mant–GDP-loaded eEF1A for the A domain alone (ZPR196–250)
is only 2-fold weaker, indicating that the binding site for eEF1A
is located primarily on the A domain. Conversely, the affinity of
mant– guanyl-5yl-imidodiphosphate-loaded eEF1A for
ZPR11–240 is two orders of magnitude lower. Finally, ZPR1 has
only a modest effect (2.5-fold decrease) on the affinity of
eEF1A for nucleotides and no detectable effect on the kinetics
of nucleotide exchange or GTP hydrolysis (SI Fig. 11). Thus,
ZPR1 preferentially recognizes the GDP-bound form of eEF1A
but does not directly influence the GTPase cycle.
ZPR1 Competes with eEF1B for Binding to eEF1A. GTP-bound
eEF1A is required for recruitment of aminoacyl tRNAs to the
A-site of the ribosome during translation elongation. GTP is
loaded onto eEF1A through the catalytic action of eEF1B, an
essential heterooligomeric complex that includes the GDP/GTP
exchange factor eEF1B (19, 20). As shown in Fig. 3B, ZPR1
competes effectively with eEF1B for binding to eEF1A, dis-
placing eEF1B from a preformed nucleotide-free eEF1A–
eEF1B complex to form a stable eEF1A–ZPR1 complex. In
contrast, eEF1B fails to displace ZPR1 from a preformed
eEF1A (GDP)–ZPR1 complex (Fig. 3B), which is consistent
with the 30-fold higher affinity of eEF1A (GDP) for ZPR1
compared with eEF1B. The simplest possibility is that ZPR1
binds to a site that overlaps with or occludes that for eEF1B.
Alternatively, ZPR1 binding might cause a change in the con-
formation of eEF1A that would decrease the affinity for
eEF1B. Although ZPR1 does not directly modulate the intrin-
sic nucleotide exchange kinetics of eEF1A (SI Fig. 11), the
results presented here suggest that ZPR1–eEF1A complexes in
cells would be resistant to nucleotide exchange catalyzed by
eEF1B and might contribute to the regulation of translation
elongation or otherwise play a distinct role in cell proliferation.
Mutational Analyses of eEF1A-Binding Epitope. To locate the bind-
ing site for eEF1A and identify key interaction determinants,
conserved surface residues in the ZnF1-A domain module were
substituted with alanine, and the binding affinity for mant–GDP-
loaded eEF1A was quantified as described above (Fig. 4A and SI
Fig. 12). All of the mutants characterized expressed in a soluble
form at levels comparable with the wild-type protein. As shown
in Fig. 4B, the majority of substitutions had a relatively small
effect (1- to 3-fold difference). Three single substitutions,
R164A, I175A, and F178A, decreased the binding affinity by one
to two orders of magnitude. Double (R164A, I175A) and
quadruple (R164A, I175A, F178A, K181A) mutations reduced
the binding affinity below the detection limit (1,000-fold
decrease). The four residues that are most critical for eEF1A
binding (Arg-164, Ile-175, Phe-178, and Lys-181) are clustered
on the surface of the helical hairpin in the A domain just above
the 4-strand (Fig. 4C). It is likely that these residues are located
within the binding epitope for eEF1A. Although not mutated,
Fig. 2. Identification of putative conserved interaction epitopes in ZPR1 for
receptors and SMN complexes. (A) Conservation of residues between ZnF1 and
ZnF2 mapped to the surface of ZPR1. (B) Conservation of exposed residues in
the ZnF2-B domain modules of ZPR1 homologues. (C) Conservation of residues
buried in the interface between ZnF2 and the B domain of ZPR1 homologues.
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three other invariant resides (Glu-129 in the 3/4 loop and
Glu-133 and Pro-135 in 4) are clustered on a proximal surface
that may also contribute to the eEF1A binding site. Between the
adjacent clusters of conserved residues, the exposed edge of the
4-strand presents backbone NH and CO groups that could
participate in polar interactions. Finally, as shown in Fig. 5A, the
single, double, and quadruple alanine substitutions of Arg-164,
Ile-175, Phe-178, and Lys-181 impair or disrupt the ability of
6xHis ZPR11–240 to coprecipitate endogenous eEF1A from
HeLa cell lysates.
Disruption of ZPR1–eEF1A Interaction Causes Growth Defects. Al-
though the ZnF1-A domain region of ZPR1 is required for
normal cell growth, proliferation, and cell cycle progression, the
functional role of the ZPR1–eEF1A complex is unclear. To
assess the functional consequences of substitutions that disrupt
the interaction with eEF1A, we investigated the effect of ZPR1
mutations on the viability of a Saccharomyces cerevisiae ZPR1
(cZPR1)-null strain. Haploid yeast with disrupted zpr1::LEU2
were complemented with wild-type cZPR1 (strain MY7) (2) and
were used to examine the effect of cZPR1 mutations by plasmid
shuffling (21) using 5-f luoroorotic acid (2). As shown in Fig. 5B,
both the wild-type andmutated cZPR1 proteins complement the
viability of the cZPR1-null strain. This result is consistent with
our earlier finding that the N-terminal region is dispensable for
viability but is required for normal growth (2). Nevertheless, the
small colony size observed for yeast complemented with cZPR1
containing double and in particular quadruple mutations sug-
gests that the interaction with eEF1A likely plays an important
role in cell growth and proliferation. Indeed, the interaction of
ZPR1 with eEF1A is induced by extracellular growth stimuli (2).
To further investigate this possibility, we compared the growth
phenotype of the cZPR1 null strain complemented with plasmids
encoding wild-type or mutated cZPR1 proteins. Control exper-
iments demonstrated that cZPR1 mutations corresponding to
substitutions that had only a small effect on eEF1A binding, such
as Q91A, exhibited normal growth (Fig. 5B). In contrast, mu-
tations corresponding to the R164A and I175A substitutions that
reduced the affinity for eEF1A by 10- to 100-fold exhibited
decreased cell growth (data not shown), whereas mutations
corresponding to the double and quadruple amino acid substi-
tutions that completely disrupted eEF1A binding caused a
profound decrease (20 fold) in growth compared with yeast
expressing wild-type cZPR1 (Fig. 5B). Furthermore, yeast
strains complemented with mutated cZPR1 containing double
and quadruple amino acid substitutions grow in clusters and
exhibit a marked (2- to 4-fold) increase in cell size (Fig. 5C Left).
Fig. 3. Characterization of the interaction between ZPR1 and eEF1A. (A) Quantitative analysis of the binding of ZPR1 constructs to eEF1A loaded with mant–GDP
or mant–guanyl-5yl-imidodiphosphate. Solid lines represent fitted model functions for a hyperbolic binding isotherm. (B) Coprecipitation of eEF1A or the
preformed eEF1A–eEF1B116–206 complex with GST–ZPR11–240. Note that eEF1A and GST-ZPR11–240 have identical mobility on SDS/PAGE. (C) Coprecipitation of
eEF1A or the preformed eEF1A–His6 ZPR11–240 complex with GST–eEF1B116–206.
Fig. 4. Structure-based mutational analysis of the ZPR1–eEF1A interaction.
(A) Distribution of conserved residues in the ZnF1-A domain region of ZPR1. (B)
Effect of ZPR1 mutations on the interaction with eEF1A (mean  SD, n 	 2).
The expression, solubility, and stability of the wild-type and mutant proteins
were similar. (C) Binding affinity of ZPR1 mutants for eEF1A (relative to
wild-type ZPR1) mapped to the surface of the ZnF1-A domain module of ZPR1.








ZPR1-eEF1A Interaction Is Required for Normal Cell Cycle Progression.
To determine the effect of disrupting the interaction with
eEF1A on cell cycle progression, we examined the distribution
of yeast cells in different phases of the cell cycle. Analysis of the
DNA content by flow cytometry indicates that cZPR1 null cells
complemented with wild-type or mutated cZPR1 proteins (e.g.,
Q91A) that do not disrupt interaction with eEF1A are distrib-
uted among the G1, S, and G2 phases of the cell cycle, corre-
sponding to 1N and 2N DNA content, respectively (Fig. 5C
Right). In contrast, cZPR1-null cells complemented with cZPR1
containing the double and quadruple mutations were distributed
between the G1 and G2 phases of the cell cycle. The distribution
of cells (65% contain 2N DNA in the G2 phase) and larger size
are indicative of G2/M phase accumulation. These results are
consistent with the recent finding that reduced ZPR1 expression
causes accumulation of mammalian cells in the G1 and G2 phases
of the cell cycle (6) and support the conclusion that the inter-
action of ZPR1 with eEF1A is required for normal cell cycle
progression.
Discussion
The crystal structure of a ZPR1 domain tandem provides insight
into the tertiary structure and organization of the individual
ZPR1 domain modules. There are few intramolecular contacts
between ZnF1 and the A domain, indicative of a modular
organization. Earlier studies established that either Zn2 finger
is sufficient for receptor binding, whereas eEF1A binding is
disrupted by deletions in the A domain. Here, we find that the
A domain is sufficient as well as necessary for eEF1A binding.
Thus, both the structural and biochemical data support the
conclusion that ZnF1 and the A domain function as independent
binding modules. In contrast, ZnF2 and the B domain adopt a
specific organized tertiary structure with a substantial interface
composed of conserved residues. Furthermore, the conserved
surface-exposed residues in the ZnF2-B domain module are
clustered within two distinct patches that extend over both
domains. These observations suggest the possibility of a con-
certed binding modality. Given that ZnF2 is sufficient for
receptor binding, such a concerted binding modality would
evidently involve the SMN complexes or other unknown part-
ners. Further investigation awaits identification of the specific
components of the SMN complex and/or other factors that
mediate interactions with the ZnF2-B domain module. Finally,
as a consequence of the disordered linker, we cannot unambig-
uously resolve whether the observed contact between the A
domain and ZnF2 is crystallographic or intramolecular.
The apparently organized tertiary structure of the ZnF2-B
domain module may also be related to the observation that
cZPR1 nuclear export requires the cis–trans prolyl isomerase
activity of cyclophilin A (22). Although not an essential gene,
cyclophilin A exhibits specific synthetic lethality with three
cZPR1 alleles that belong to the same complementation group.
Two of the alleles involve a common single amino acid substi-
tution in which an invariant aspartic acid is replaced by aspar-
agine. The third allele encodes a single substitution in which an
invariant glycine residue is replaced by aspartic acid. The cor-
responding aspartic acid and glycine residues in the ZPR1
structure are located at the C terminus of 7 in the B domain and
at the C terminus of ZnF2, respectively. Although all of the
proline residues in the ZPR1 crystal structure adopt the trans
configuration, cis isomers might occur in vivo. Indeed, it has been
proposed (23) that the highly conserved proline following the
invariant aspartic acid might undergo a native state cis–trans
isomerization switch analogous to the proline isomerization
switch that modulates ligand recognition in the SH2 domain of
the IL-2 tyrosine kinase (24). The proline residue in ZPR1 is
located at the N terminus of the 6/7-loop, the conformation
of which would necessarily be altered by cis–trans isomerization.
Given that the 6/7-loop occupies the core of the intramolec-
ular interface between ZnF2 and the B domain, it is likely that
the latter interface also would be affected. Finally, the only
obvious connection between the invariant aspartic acid in the B
domain and the invariant glycine in ZnF2 is their proximity to the
ZnF2-B domain interface. Thus, local structural perturbations
induced by the asparagine and aspartic acid substitutions may
indirectly affect the cis–trans equilibrium of the conserved
proline in the 6/7-loop through destabilization of the ZnF2-B
domain interface.
Consistent with broad evolutionary conservation in eukaryotic
organisms, ZPR1 is essential for viability in yeast and mice (2, 5).
Whereas the ZnF2-B domain module is essential for viability in
yeast, the ZnF1-A domain is required for normal growth, prolif-
eration, and cell cycle progression (2). It also had been observed
that eEF1A binding is disrupted by deletion of a highly conserved
20-residue region in the A domain. This deletion, which eliminates
the 6/7-loop as well as most of the 6- and 7-strands, would be
expected to compromise the tertiary structure of the -helix.
Therefore, the loss of eEF1A binding is likely to be a secondary
consequence of a structural defect. In the present study, we have
used a structure-based mutational analysis of conserved surface
residues to identify critical determinants in the eEF1A binding
epitope. Individual substitutions involving four conserved residues
in the helical hairpin substantially reduced the affinity for eEF1A
without affecting the expression levels or solubility of the protein.
Furthermore, complementation experiments demonstrated that
double and quadruple substitutions that abolish eEF1A binding
restore the viability of the ZPR1-null strain but exhibit growth,
proliferation, and cell cycle defects similar to those previously
reported for constructs that delete the ZnF1-A domainmodule (2).
Fig. 5. Mutations that disrupt eEF1A binding cause growth, proliferation,
and cell cycle defects in yeast. (A) Immunoblot analysis of the effect of ZPR1
mutations on the binding of human eEF1A. The His6-tagged fusion proteins
were purified, immobilized on Ni2-NTA-agarose, and used for binding assays
using HeLa cell lysates. Bound eEF1A was detected with anti-eEF1A antibody.
(B) Growth of haploid yeast strains (zpr1::LEU2) complemented with plasmid
expression vectors encoding wild-type and mutated cZPR1 proteins. Liquid
cultures (0.1 OD600) were serially diluted 10-fold, spotted onto yeast extract
peptone dextrose plates, and incubated at 30°C. (C) (Left) The morphology of
haploid yeast strains (zpr1::LEU2) complemented with plasmid expression
vectors encoding wild-type and mutated cZPR1 proteins was examined by
differential interference confocal (DIC) microscopy. (Scale bar, 6.0m.) (Right)
Also shown are the results of flow cytometric analyses using FACS of the
haploid yeast strains expressing wild-type and mutated cZPR1.
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Although these results provide strong evidence that the in-
teraction with eEF1A is required for normal growth, prolifera-
tion, and cell cycle progression, the underlying mechanism of
action remains to be determined. The observation that ZPR1
binds preferentially to the GDP-loaded form of eEF1A but has
a negligible effect on nucleotide affinity, as well as the kinetics
of GDP/GTP exchange and GTP hydrolysis, supports the con-
clusion that ZPR1 does not function within the context of the
conventional GTPase paradigm as an effector, guanine nucle-
otide exchange factor, or GTPase activating protein. Neverthe-
less, the ability to efficiently displace eEF1B from preformed
complexes with eEF1A suggests that ZPR1 might indirectly
regulate the GTPase cycle of eEF1A by interfering with eEF1B-
catalyzed activation. Thus, after release from receptors in mi-
togen/nutrient-stimulated cells, ZPR1 may act as a negative
regulator of eEF1A. It also is possible that ZPR1–eEF1A
complexes have an eEF1B-independent function in translation
and/or other cellular processes that require eEF1A, such as
regulation of the actin cytoskeleton (25, 26).
The studies presented here provide insights into the structural
and mechanistic bases underlying the essential function of the
evolutionarily conserved ZPR1 protein. We anticipate that the
ZPR1 structure will continue to provide a valuable framework
for structure–function analyses of the mechanisms through
which ZPR1 regulates fundamental cellular processes in both
dividing as well as terminally differentiated cells, including
neurons.
Materials and Methods
Constructs. Constructs of mouse ZPR1 (residues 1–459, 46–440,
1–240, 96–250, and 246–459) and S. cerevisiae eEF1B (residues
1–206 and 116–206) were amplified and subcloned into pGEX-
6P1 (Amersham Pharmacia Biotech, Piscataway, NJ) for expres-
sion as GST fusions or into a modified pET15b vector, which
incorporates an N-terminal His6 tag (MGHHHHHHGS). Site-
specific mutations were generated with the QuikChange kit
(Stratagene, La Jolla, CA). All constructs were verified by
sequencing the entire coding region.
Crystallization and Structure Determination. Selenomethionine-
substituted mouse ZPR1 (residues 46–440) was crystallized at
18°C in hanging drops containing 20 mg/ml protein in 14% PEG
6000/0.2 M ammonium sulfate/0.1 M Tris, pH 8.0/10% glycerol/2
mM Tris(2-carboxyethyl)phosphine hydrochloride. Crystals ap-
peared within 3–4 days and grew to maximum dimensions of
0.3 
 0.2 
 0.2 mm over 3 weeks. The crystals are in the
C-centered monoclinic space group C2 with cell constants a 	
55.7 Å, b 	 142.6 Å, and c 	 67.2 Å, with one molecule in the
asymmetric unit. Crystals were transferred to a cryostabilizer
solution (4.0 M lithium formate), f lash-frozen in liquid propane,
and maintained at 100 K in a nitrogen cryostream. Diffraction
data at the peak wavelength of the selenium edge were collected
at the National Synchrotron Light Source, beamline X25; pro-
cessed with Denzo (HKL Research, Charlottesville, VA); and
scaled with Scalepack (HKL Research) (27). The structure was
determined by single-wavelength anomalous diffraction. Twelve
Se sites were identified independently by Pattersonmethods with
SOLVE (28) and direct methods with SnB (29) using the Bijvoet
differences at the f  maximum. The heavy atom model was
refined with SHARP (30). Single-wavelength anomalous dif-
fraction phases were improved by solvent flipping with SO-
LOMON (31). A A-weighted Fourier summation yielded an
interpretable map with continuous density for the main chain
and most side chains. An initial model generated by ARP/wARP
(European Molecular Biology Laboratory, Heidelberg, Ger-
many) (32) was completed by manual building using O (33). The
model was refined in several iterative cycles by using ARP/wARP
and Refmac5 (32). The refined model includes residues 47–234
and 245–440. Additional information related to the structure
determination and refinement is compiled in SI Table 1. Struc-
tural Figures were rendered with PyMol.
For additional information, see SI Materials and Methods.
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